Oncotarget

Research Papers: Gerotarget (Focus on Aging):

Loss of myocardial protection against myocardial infarction in middle-aged transgenic mice overexpressing cardiac thioredoxin-1

Verónica D´Annunzio, Virginia Perez, Tamara Mazo, Marina C. Muñoz, Fernando P. Dominici, María C. Carreras, Juan José Poderoso, Junichi Sadoshima and Ricardo J. Gelpi _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:11889-11898. https://doi.org/10.18632/oncotarget.7726

Metrics: PDF 1677 views  |   HTML 2189 views  |   ?  


Abstract

Verónica D´Annunzio1,5,*, Virginia Perez1,*, Tamara Mazo1, Marina C. Muñoz2,5, Fernando P. Dominici2,5, María C. Carreras3,5, Juan José Poderoso3,5, Junichi Sadoshima4 and Ricardo J. Gelpi1,5

1 Institute of Cardiovascular Physiopathology and Department of Pathology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina

2 Institute of Chemistry and Biological Physical Chemistry, School of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina

3 Laboratory of Oxygen Metabolism, University Hospital, University of Buenos Aires, Buenos Aires, Argentina

4 Department of Cell Biology and Molecular Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA

5 Member of the National Council of Scientific and Technological Research (CONICET), Buenos Aires, Argentina

* These authors have contributed equally to this work

Correspondence to:

Ricardo J. Gelpi, email:

Keywords: myocardial infarction, ischemia/reperfusion, thioredoxin-1, middle-aged, Gerotarget

Received: December 21, 2015 Accepted: January 30, 2016 Published: February 25, 2016

Abstract

Thioredoxin-1 (Trx1) protects the heart from ischemia/reperfusion (I/R) injury. Given that the age at which the first episode of coronary disease takes place has considerably decreased, life at middle-aged (MA) emerges as a new field of study. The aim was determine whether infarct size, Trx1 expression and activity, Akt and GSK-3β were altered in young (Y) and MA mice overexpressing cardiac Trx1, and in a dominant negative (DN-Trx1) mutant of Trx1. Langendorff-perfused hearts were subjected to 30 minutes of ischemia and 120 minutes of reperfusion (R). We used 3 and 12 month-old male of wild type (WT), Trx1, and DN-Trx1. Trx1 overexpression reduced infarct size in young mice (WT-Y: 46.8±4.1% vs. Trx1-Y: 27.6±3.5%, p < 0.05). Trx1 activity was reduced by 52.3±3.2% (p < 0.05) in Trx1-MA, accompanied by an increase in nitration by 17.5±0.9%, although Trx1 expression in transgenic mice was similar between young and middle-aged. The expression of p-Akt and p-GSK-3β increased during reperfusion in Trx1-Y. DN-Trx1 mice showed neither reduction in infarct size nor Akt and GSK-3β phosphorylation. Our data suggest that the lack of protection in Trx1 middle-aged mice even with normal Trx1 expression may be associated to decreased Trx1 activity, increased nitration and inhibition of p-Akt and p-GSK-3β.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7726